At a glance
- Originator Santen Pharmaceutical
- Class Antihypertensives; Heart failure therapies
- Mechanism of Action ACE inhibitors; Endopeptidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Heart failure; Hypertension
Most Recent Events
- 20 May 2004 Suspended - Preclinical for Heart failure in Japan (PO)
- 20 May 2004 Suspended - Preclinical for Hypertension in Japan (PO)
- 04 Dec 2003 No development reported - Preclinical for Heart failure in Japan (PO)